Alpha-melanocyte-stimulating hormone is thirteen residues long. KPV is the last three of them. Everything in the parent hormone that binds a melanocortin receptor has been removed, and what is left is a molecule of 342 daltons that still does something in inflammation models — which is the entire reason anyone studies it.
That makes KPV an unusual entry on this shelf. Most fragment compounds are interesting for what they retain. KPV is interesting for what it lacks, and for a second fact that follows from its size: at three residues it fits a transporter that a four-residue peptide would not. Its length is not a detail of its description. It is the proposed mechanism.
What was removed
Alpha-MSH is a post-translational product of proopiomelanocortin, corresponding to residues 138–150 of the human POMC precursor (UniProt P01189), with the sequence SYSMEHFRWGKPV. KPV is residues 11–13 of that hormone — the C-terminal tripeptide.
The core melanocortin pharmacophore is His-Phe-Arg-Trp, sitting at positions 6–9. It is entirely outside KPV. Brzoska and colleagues put this plainly in their 2010 review (Adv Exp Med Biol 2010;681:107–116): KPV "lacks the entire sequence motif required for binding to any of the known MC-Rs," yet retains much of the anti-inflammatory capacity of the full hormone while showing no pigmentary action.
So the vocabulary of receptor pharmacology — affinity, efficacy, subtype selectivity, bias — does not describe this compound, for the same structural reason it does not describe FOXO4-DRI or MOTS-c. The melanocortin system is the parent's story, not KPV's.
It is not a small alpha-MSH
The most useful single paper here is Getting, Schiöth and Perretti (J Pharmacol Exp Ther 2003;306:631–637), because it ran the parent and the fragment side by side in one model of crystal-induced peritonitis.
Systemic KPV, alpha-MSH, the HFRW core peptide, and the MC3/4R agonist MT-II all reduced leukocyte accumulation. An MC1R-selective agonist did not. The MC3/4R antagonist SHU9119 did not block KPV's effect. KPV also worked in recessive yellow (e/e) mice, which carry a non-functional MC1R.
Then the divergence. In vitro, macrophage activation — measured as KC and IL-1β release — was inhibited by alpha-MSH and MT-II but not by KPV. MT-II raised cAMP; KPV did not. The authors concluded that KPV is unlikely to act through melanocortin receptors and is more likely acting through inhibition of IL-1β functions.
Two other findings sit alongside it. Elliott et al (J Invest Dermatol 2004;122:1010–1019) detected no cAMP elevation in human keratinocytes in response to alpha-MSH, KPV or ACTH peptides. And Kannengiesser et al (Inflamm Bowel Dis 2008;14:324–331) found KPV active in two colitis models and reported that it rescued MC1R-deficient animals, concluding the effects are "at least partially independent of MC1R signalling."
The honest read is not that KPV is a cheaper alpha-MSH. It does some of what its parent does, fails to do other parts, and reaches its effects by a route the parent does not need. A fragment shares a sequence with its source, not an evidence file.
Three residues, one transporter
Dalmasso et al (Gastroenterology 2008;134:166–178) supplied the mechanism that now defines the compound. Nanomolar KPV inhibited NF-κB and MAP kinase signalling and reduced pro-inflammatory cytokine secretion in intestinal epithelial and immune cells. Uptake was attributed to PepT1, using cold KPV as a competitor against a radiolabelled PepT1 substrate and [³H]KPV to establish uptake kinetics. Orally administered KPV reduced colitis incidence in two murine models.
PepT1 is a proton-coupled transporter that carries di- and tripeptides — the substrate range, the alternating-access mechanism and the physicochemical factors that modulate it were reviewed recently by Xu, Zhao and Yu (Food Chem 2025;496:146851). That range is the point. A tetrapeptide is already outside it. KPV has a documented route into the cytosol because it is three residues long, which is a narrow architectural coincidence rather than a general delivery strategy, and it is one of the few concrete answers on this shelf to the cell entry question.
The strongest version of the claim is genetic rather than pharmacological. Viennois et al (Cell Mol Gastroenterol Hepatol 2016;2:340–357) used mice overexpressing human PepT1 and mice with PepT1 deleted. KPV prevented carcinogenesis in wild-type animals in an AOM/DSS model; in PepT1-knockout mice, KPV produced none of the inhibitory effects seen in wild-types.
One caveat belongs next to that. Dalmasso 2008 and Viennois 2016 share a senior author, so the transporter account rests substantially on a single research lineage — the same question this site asks of Epithalon and BPC-157. A knockout is strong evidence. That it comes from one group is a separate fact, and both are true.
Where the recent literature actually went
Search KPV in 2025–2026 and you mostly do not find people testing whether KPV works. You find three other things.
KPV as an address rather than an active. Because PepT1 is upregulated in inflamed colonic epithelium, the tripeptide has become a targeting ligand. It has been conjugated to a fluorophore to image colitis activity (ACS Appl Mater Interfaces 2017;9:13029–13036), attached to nanoparticles delivering cyclosporine A (Biomater Sci 2019;7:4299–4309), and used to decorate deformable liposomes carrying Nlrp3 shRNA to melanocytes in a vitiligo model (Cell Death Differ 2026;33:343–357). In this work the peptide is the postcode and something else is the drug.
Delivery engineering that diagnoses the limitation. Cheng et al (Sci Adv 2026;12(3):eaea2989) built self-immolative prodrug conjugates and reported that the KPV conjugate achieved 3.8-fold greater colonic accumulation than free KPV, with efficacy retained at a twenty-fold lower amount. Surrounding it are hydrogels for oral mucositis (Biomater Sci 2021;10:227–242), a skin-adaptive film (Int J Biol Macromol 2022;222:2729–2743), a biomimetic-mucus hydrogel (ACS Appl Mater Interfaces 2024;16:7686–7699), and oil-layered microspheres built specifically to carry KPV through gastric conditions intact (ACS Appl Bio Mater 2025;8:2251–2262). When the active research programme is about getting a molecule to arrive, arrival is the unsolved part — the same signal read here for VIP and for intranasal oxytocin.
New phenotypes from a new group. A team at Pukyong National University has run KPV through keratinocytes exposed to particulate matter (Tissue Cell 2025;95:102837, with one author from a company research institute), HepG2 steatosis (Cytotechnology 2026;78:98), and 3T3-L1 adipogenesis with a high-fat-diet mouse arm (Tissue Cell 2026;104:103837), converging on ROS-dependent AKT/mTORC1/PPARγ signalling.
Two reading notes on that series. The reported assay concentrations are around 50–100 µg/mL, which for a 342 Da peptide works out to hundreds of micromolar — roughly five orders of magnitude above the nanomolar activity Dalmasso attributed to PepT1 uptake. These are not the same experiment, and in-vitro concentrations are assay parameters, not doses. Second, PepT1 expression is documented in intestinal epithelium and immune cells; it is not established in keratinocytes or adipocytes. How KPV got inside those cells is unaddressed.
The human file, and the registry
There is no published human administration of KPV. The papers that appear in a search for human work used human cells: bronchial epithelial cells (Int J Physiol Pathophysiol Pharmacol 2012;4:59–73) and peripheral blood mononuclear cells for the dimeric derivative (CKPV)₂ (J Surg Res 2006;131:209–214).
Searched against the ClinicalTrials.gov v2 API today, KPV returns zero records — not zero results, zero registrations. There is no intention on file, which places it below the third rung of the evidence hierarchy entirely, the same position occupied by Epithalon and Thymalin. There is no US drug label.
What 2026 did produce is review traffic that names the compound. A critical review in J Sports Med Phys Fitness (2026;66:880–885) lists KPV among marketed peptides and states that clinical evidence is limited and supply chains unregulated. Drug Discov Today (2025;30:104535) places it within host-defense-peptide work on inflammatory bowel disease, and a tripeptide wound-healing review (Int J Med Sci 2025;22:4175–4200) covers KPV-loaded hydrogels alongside GHK-Cu formulations. These acknowledge the gap rather than filling it.
Name traps and what paperwork can answer
KdPT is not a KPV variant in the way the name implies. It is routinely introduced as a KPV derivative, but it corresponds to residues 193–195 of IL-1β (Luger & Brzoska, Ann Rheum Dis 2007;66 Suppl 3:iii52–55) — a different parent protein. (CKPV)₂ is a dimer. Shared letters here do not mean shared lineage, the recurring lesson of peptide nomenclature.
The C-terminus is an open question on the label. In alpha-MSH, Val150 is amidated (UniProt P01189), so the C-terminal tripeptide as it exists in the hormone is KPV-amide. The CAS number carried on catalog records for this compound, 67727-97-3, resolves in PubChem to CID 125672, C16H30N4O4, 342.43 — the free acid. Those two species are about 1 Da and one unit of net charge apart, the same distinction that separates Melanotan 2 from PT-141. Much of the published work writes "KPV" with no C-terminal annotation; some specifies (H-KPV-NH₂ and Ac-KPV-NH₂ appear in PLoS One 2018;13:e0199686). A theoretical mass is only checkable if it states which species is meant.
Three residues have six possible orders. All six permutations share an identical composition and an identical mass. Amino acid analysis counts residues; intact mass weighs them. Neither can distinguish KPV from KVP or VPK. That needs MS/MS sequence confirmation — and with two amide bonds the entire ladder is two fragment pairs, with proline sitting at position 2, exactly where collision-induced dissociation preferentially cleaves.
Mass accounting gets harder as molecules get smaller, not easier. KPV has two basic sites, the lysine side chain and the free N-terminus. Against a 342 Da peptide, a di-trifluoroacetate salt would be roughly 60% peptide by weight before any residual water is counted. That is composition rather than a defect — but it means net peptide content is more load-bearing here than on a 4 kDa sequence, not less. And with no tryptophan or tyrosine, A280 quantitation is unavailable, as with BPC-157, Epithalon and Selank. More on these axes at /quality/.
FAQ
Is KPV effectively a cheaper alpha-MSH? No. The literature's own comparison found it reproduces part of the parent's anti-inflammatory profile, fails to reproduce other parts, raises no cAMP, and carries none of the sequence required to bind a melanocortin receptor.
Does the PepT1 finding mean an oral route works? It means an uptake route exists in tissue that expresses the transporter, demonstrated by competition, kinetics and a knockout. It is worth reading next to the fact that the 2026 delivery literature is built on the premise that free KPV largely does not arrive where it is aimed.
Why is it shelved under healing-recovery? Filing convenience, not pharmacology. Its research literature is inflammatory signalling, which is why it appears repeatedly in the immune class primer rather than the repair one. Category labels on this catalog describe navigation, not mechanism. Full index at /library/.
This article is educational and for the laboratory research community. Trulogic Labs products are sold for laboratory and research use only and are not for human consumption.